SSelectStock
Sign in

ONESOURCEOnesource Specialty Pharma Limited

Pharma · Biotechnology · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

1,693.90
2.46%
44Weak

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)18,957.20
P/E
P/B3.26
PEG
ROE %-1.26
ROCE %0.30
Debt / Equity0.26
EPS-6.43
Revenue Growth %0.50
Profit Growth %-95.30
Dividend Yield %0.00
Promoter Holding %38.04
FII Holding %33.33
DII Holding %
Beta-0.15

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Cup & HandleLONG82%1,693.901,616.902,078.905.00
Pullback to 21-EMALONG57%1,693.901,606.701,827.201.53
HOLDConviction 60%

The picture

  • Debt/Equity: 0.26
  • RSI: 57
  • MACD: bullish
  • Price vs EMA21: above
  • 1-month vs NIFTY: +5.0% relative
  • 3-month vs NIFTY: +5.6% relative
  • Cup & Handle signal (setup quality 82%)
  • Pullback to 21-EMA signal (setup quality 57%)

Bull case

  • Debt/Equity: 0.26
  • RSI: 57
  • MACD: bullish
  • Price vs EMA21: above

Bear case

  • Revenue growth: 0.5% YoY
  • Profit growth: -95.3% YoY
  • Price vs SMA50: below
  • Supertrend: bearish

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Weak fundamentals — technical strength may not sustain
  • Revenue growth: 0.5% YoY
  • Profit growth: -95.3% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,693.90
Stop Loss
₹1,525.22
risk 10%
Target 1 (1.5R)
₹1,946.93
+14.9%
Target 2 (3R)
₹2,199.95
+29.9%
Support (20d)
₹1,506.10
Resistance (52w)
₹2,088.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹168.68/share
ATR (volatility)
₹67.47
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹67.47). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
19
Technical
60
Momentum
56
Risk (safety)
38

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.